- $11.43bn
- $18.68bn
- $8.25bn
- 57
- 56
- 79
- 69
Annual income statement for Solventum, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | PROSPECTUS | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 7,281 | 8,171 | 8,130 | 8,197 | 8,254 |
| Cost of Revenue | |||||
| Gross Profit | 4,315 | 4,923 | 4,695 | 4,693 | 4,612 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 5,851 | 6,292 | 6,437 | 6,505 | 7,218 |
| Operating Profit | 1,430 | 1,879 | 1,693 | 1,692 | 1,036 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 1,440 | 1,882 | 1,692 | 1,667 | 605 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 1,138 | 1,460 | 1,343 | 1,346 | 478 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 1,138 | 1,460 | 1,343 | 1,346 | 478 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 1,138 | 1,460 | 1,343 | 1,346 | 479 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 6.74 | 8.52 | 7.85 | 7.87 | 3.04 |